Every life sciences company knows that patient safety is non negotiable, but the way safety is managed—and the value ...

Artificial intelligence has moved from pilot projects to a central role in many life sciences strategies. What began as a set ...

Caris Life Sciences Inc. CAI shares are up during Friday’s premarket session following better-than-expected fourth-quarter earnings and a significant interim readout from the company’s Achieve 1 study ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

A colorectal cancer blood test candidate from Exact Sciences fell short in its pivotal study, but the company is still in the hunt to provide an alternative to the liquid biopsy that was first to ...

Caris projects 2026 total revenue in the range of $1.0 billion to $1.02 billion, anticipating molecular profiling growth of approximately 21% to 22%, and therapy selection volume growth of around 20% ...

Exact Sciences Corp. (NASDAQ:EXAS) is one of 15 stocks with the biggest hedge fund momentum, after gaining 31 hedge fund ...

Family and consumer sciences professionals shape lives daily, support communities and quietly power some of the country’s most essential industries. For years, the value of that work has been clear to ...

The labs are not all right. After years of new supply without the tenant demand to support it, life sciences real estate nationwide is at an inflection point, with 18.7M SF likely to change uses by ...

Following a difficult start in 2025, the ever-evolving life sciences segment recovered strongly in the latter half of the year.